Roivant Sciences Ltd. (ROIV) is listed on NASDAQ in Pharmaceutical Stocks. It is $34.70, -7.68%, with a $25.1B market cap. RSI is 44.3, neutral. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 44.3 Neutral
Market Cap $25.1B
Volume 4.9M
Fundamentals — 10-Q Q1 2026
Revenue $1.4M
Net Income $-189.8M
EPS $-0.26
Operating Margin -25380.9%
Net Margin -13164.8%
P/E Ratio -133.4x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Sukhatme Mayukh | President & CIO | Sell | 335,174 | $36.88 | $12.4M | 2026 Aug 21 |
| Sukhatme Mayukh | President & CIO | Sell | 664,826 | $36.34 | $24.2M | 2026 Aug 18 |
| Venker Eric | President & Immunovant CEO | Sell | 200,000 | $34.95 | $7.0M | 2026 Jul 27 |
| Fitzgerald Meghan | Director | Sell | 10,000 | $34.90 | $349,000 | 2026 Jun 30 |
| Manchester Keith S | Insider | Sell | 1,638,163 | $34.46 | $56.4M | 2026 Jun 30 |
| Gold Daniel Allen | Insider | Sell | 1,438,163 | $34.32 | $49.4M | 2026 Jun 30 |
| Qvt Financial LP | Insider | Sell | 1,438,163 | $34.32 | $49.4M | 2026 Jun 30 |
| Epperly Melissa B, | Director | Sell | 17,750 | $34.38 | $610,252 | 2026 Jun 29 |
| Sukhatme Mayukh | President & CIO | Sell | 1,000,000 | $34.10 | $34.1M | 2026 Jun 26 |
| Venker Eric | President & Immunovant CEO | Sell | 200,000 | $33.16 | $6.6M | 2026 Jun 24 |
| Venker Eric | President & Immunovant CEO | Sell | 200,000 | $30.27 | $6.1M | 2026 May 22 |
| Venker Eric | President & Immunovant CEO | Sell | 200,000 | $29.59 | $5.9M | 2026 Apr 20 |
| Gline Matthew | CEO | Sell | 289,774 | $29.16 | $8.4M | 2026 Apr 16 |
| Humes Jennifer | Chief Accounting Officer | Sell | 13,538 | $28.37 | $384,073 | 2026 Apr 8 |
| Fitzgerald Meghan | Insider | Sell | 70,000 | $27.45 | $1.9M | 2026 Mar 26 |
| Venker Eric | President & Immunovant CEO | Sell | 200,000 | $28.24 | $5.6M | 2026 Mar 17 |
| Epperly Melissa B, | Director | Sell | 41,861 | $28.68 | $1.2M | 2026 Mar 16 |
| Torti Frank | President and Vant Chair | Sell | 3,000,000 | $27.35 | $82.0M | 2026 Feb 23 |
| Sukhatme Mayukh | President & CIO | Sell | 1,330,868 | $21.72 | $28.9M | 2025 Dec 31 |
| Venker Eric | President & Immunovant CEO | Sell | 275,000 | $22.47 | $6.2M | 2025 Dec 24 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $20.85 | 65.2 | $2.2B |
| | $36.44 | 58.3 | $42.5B |
| | $13.17 | 50.0 | $2.7B |
| | $153.79 | 49.7 | -- |
Take ROIV further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put ROIV in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Roivant Sciences Ltd. next reports.
Set alerts on ROIV
Get notified when Roivant Sciences Ltd. hits your price targets or technical conditions are met.
Get Started Free